A New Class of TherapiesBased on a New Understanding of How the Immune System Works

EVELO BIOSCIENCES ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING
Cambridge, Mass. - May 8, 2018
EVELO BIOSCIENCES EXPANDS EXECUTIVE LEADERSHIP TEAM
Cambridge, Mass. - February 8, 2018
EVELO BIOSCIENCES ANNOUNCES ISSUANCE OF U.S. PATENT SUPPORTING MONOCLONAL MICROBIAL ONCOLOGY TRIALS
Cambridge, Mass. - January 9, 2018
EVELO BIOSCIENCES AND MAYO CLINIC COLLABORATE TO ADVANCE MONOCLONAL MICROBIALS FOR THE TREATMENT OF INFLAMMATORY AND NEUROINFLAMMATORY DISEASES
Cambridge, Mass. - November 16, 2017

Modulation of the gut-body network has therapeutic potential in major disease areas.

We are developing a new class of medicines that are designed to act on immune cells in the gut for effects throughout the body.

The gut-body network and monoclonal microbials

The gut is central to human biology and is connected to all parts of the body via the lymphatic system.
Microbes have naturally evolved to modulate systemic biology through the gut-body network.

Based on these two central principles of previously underappreciated biology, we are developing a new class of medicines – monoclonal microbials.

About our science

Our Portfolio

We are advancing multiple monoclonal microbial product candidates into clinical studies across oncology and inflammatory diseases. We dosed the first subject in our clinical trial of our first monoclonal microbial product candidate in our inflammation portfolio, EDP1066. First-in-human studies of our additional lead product candidates are expected to begin in 2018 and to deliver 10 clinical readouts across inflammatory diseases and cancer throughout 2019 and 2020.

About our portfolio

Evelo is led by a team with deep experience.

Our leadership team has founded, led and grown transformative platform biotechnology companies. Our team has also developed and commercialized medicines that have impacted many lives.

About our team

Founder and Investors

Evelo was founded by Flagship Pioneering. Flagship VentureLabs’ innovators conceived of and developed Evelo’s foundational inventions, leading to the launch of Evelo Biosciences in 2015. Additional investors in Evelo include GV (the venture capital arm of Alphabet, Inc.), Celgene, the DDF (Dementia Discovery Fund), Fidelity, Mayo Clinic and Alexandria Real Estate Equities.

Investors page